Isopimarane diterpene glycosides of endophytic fungus Xylaria sp. ZY-13

IF 1.3 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2025-04-14 DOI:10.1016/j.phytol.2025.102963

Zhang Mingyue , Song Yongqi , Chen Xiaohui , Feng Yuxiao , Shi Jiaqi , Li Yonghui , Wang Shoudong , Guo Tao

引用次数: 0

Abstract

Two previously undescribed isopimarane diterpene glycosides, namely xylarisides A (1) and B (2), along with five known analogues (3 −7), were characterized from the fermentation products of the fungus Xylaria sp. ZY-13, isolated from the medicinal plant Cephalotaxus fortunei Hook. The structural characterization and absolute stereochemistry of two previously unreported compounds were identified utilizing comprehensive modern spectroscopic approaches, electronic circular dichroism analyses, and acid hydrolysis of sugar. Additionally, we assessed the in vitro anti-inflammatory effects of all compounds, and only 7 showed weak inhibitory activities.

查看原文本刊更多论文

内生真菌 Xylaria sp. ZY-13 的异异丙基二萜苷类

从药用植物Cephalotaxus fortunei Hook中分离的Xylaria sp. ZY-13真菌的发酵产物中鉴定了两个先前未被描述的异吡马烷二萜苷，即木苷A(1)和B(2)，以及五个已知的类似物（3 −7）。利用综合的现代光谱方法、电子圆二色分析和糖的酸水解，确定了两种以前未报道的化合物的结构表征和绝对立体化学。此外，我们评估了所有化合物的体外抗炎作用，只有7种化合物表现出较弱的抑制活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.